Rare Cancers Australia (RCA) has welcomed the latest TGA approval of Novartis' targeted cancer combination TAFINLAR (dabrafenib) and MEKINIST (trametinib).
Rare Cancers Australia calls for rapid funding of paediatric brain cancer combination
March 6, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
Stakeholder backing for another PBS co-pay reduction
March 20, 2025 - - Latest News -
If our own government isn't going to do anything, then we can only hope for intervention
March 20, 2025 - - Latest News -
US price negotiation power reveals a very different approach to patient input
March 20, 2025 - - Latest News -
Brisbane-based drugmaker QBiotics celebrates 25 years since its creation
March 19, 2025 - - Australian Biotech -
Imugene's azer-cel granted FDA Fast Track Designation in blood cancer
March 19, 2025 - - Australian Biotech -
Island raises $2.72 million through exercise of listed options
March 19, 2025 - - Australian Biotech -
All manufacturers decide to participate in the second cycle of US price negotiation
March 19, 2025 - - Latest News